Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity

Clinical Pharmacokinetics

Volumn 46, Issue 4, 2007, Pages 319-333

  Wilde, Stefan ^a   Jetter, Alexander ^a   Rietbrock, Stephan ^a   Kasel, Dirk ^a,i   Engert, Andreas ^a,b   Josting, Andreas ^a,b   Klimm, Beate ^a,b   Hempel, Georg ^c   Reif, Stefanie ^d   Jaehde, Ulrich ^d,e   Merkel, Ute ^f   Busse, Dagmar ^g   Schwab, Matthias ^g,h   Diehl, Volker ^a   Fuhr, Uwe ^a,j  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b German Hodgkin Study Group   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

^e UNIVERSITY OF BONN   (Germany)

^f FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^g DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁱ GRÜNENTHAL GMBH   (Germany)

^j UNIVERSITY OF COLOGNE   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DOXORUBICIN; DRUG METABOLITE; ETOPOFOS; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BODY SURFACE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; HODGKIN DISEASE; HUMAN; MALE; PLATELET TOXICITY; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT DURATION; URINARY EXCRETION;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; BODY SURFACE AREA; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ETOPOSIDE; HODGKIN DISEASE; HUMANS; MIDDLE AGED; PHENOTYPE; PLATELET COUNT; PREDNISONE; PROCARBAZINE; VINCRISTINE;

EID: 33947713308     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200746040-00005     Document Type: Article

References (58)

1. Diehl V, Sieber M, Ruffer U, et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. Ann Oncol 1997; 8: 143-8
2. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-95
3. Engel C, Loeffler M, Schmitz S, et al. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). Ann Oncol 2000; 11: 1105-14
4. Diehl V, Franklin J, Hasenclever D, et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 1998; 16: 3810-21
5. Tesch H, Diehl V, Lathan B, et al. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. Blood 1998; 92: 4560-7
6. Klimm B, Reineke T, Haverkamp H, et al. Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group. J Clin Oncol 2005; 23: 8003-11
7. Brosteanu O, Hasenclever D, Loeffler M, et al. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease. Ann Hematol 2004; 83: 176-82
8. Bergh J. Adjuvant chemotherapy for breast cancer: "one fits all"? Breast 2005; 14: 564-9
9. McLeod HL, Evans WE. Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins. Cancer Surv 1993; 17: 253-68
10. Veal GJ, Coulthard SA, Boddy AV. Chemotherapy individualization. Invest New Drugs 2003; 21: 149-56
11. Fuhr U, Kirchheiner J. Individual variation in the many steps from dosing to antineoplastic effects. Int J Clin Pharmacol Ther 2005; 43: 573-4
12. Liliemark J, Peterson C. Pharmacokinetic optimisation of anti-cancer therapy. Clin Pharmacokinet 1991; 21: 213-31
13. Sandström M, Lindman H, Nygren P, et al. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin- cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol 2006; 58: 143-56
14. Ette EI, Kelman AW, Howie CA, et al. Interpretation of simulation studies for efficient estimation of population pharmacokinetic parameters. Ann Pharmacother 1993; 27: 1034-9
15. Mentre F, Burtin P, Merle Y, et al. Sparse-sampling optimal designs in pharmacokinetics and toxicokinetics. Drug Information J 1995; 29: 997-1019
16. Rietbrock S. Optimal sampling designs in studies on population kinetics of antineoplastic agents. Eur J Clin Pharmacol 1997; 52: A15
17. Hardy RW, Erlichman C, Soldin SJ. High-performance liquid chromatographic measurement of cyclophosphamide in serum. Ther. Drug Monit 1984; 6: 313-8
18. Hempel G, Schulze-Westhoff P, et al. Therapeutic drug monitoring of doxorubicin in paediatric oncology using capillary electrophoresis. Electrophoresis 1998; 19: 2939-43
19. Stremetzne S, Jaehde U, Schunack W. Determination of the cytotoxic catechol metabolite of etoposide (3′O-demethyletoposide) in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997; 703: 209-15
20. Huber F, Wiedemann M, Heinrich G, et al. Development of a high performance liquid chromatography method for the simultaneous measurement of prednisone and prednisolone. Arzneimittelforschung 1990; 40: 926-31
21. Kasel D, Jetter A, Harlfinger S, et al. Quantification of cyclophosphamide and its metabolites in urine using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2004; 18: 1472-8
22. Shiba DA, Weinkam RJ. Quantitative analysis of procarbazine, procarbazine metabolites and chemical degradation products with application to pharmacokinetic studies. J Chromatogr B Biomed Sci Appl 1982; 229: 397-407
23. Kasel D, Jetter A, Wilde S, et al. Urinary procarbazine excretion during the BEACOPP polychemotherapy regimen in patients with Hodgkin's disease. Eur J Clin Pharmacol 2001; 57 : A32
24. Busse D, Kroemer HK. Dose-dependancy of oxazaphosphorine pharmacokinetics. Int J Clin Pharmacol Ther 1997; 35: 71-2
25. de Jonge ME, Huitema AD, Rodenhuis S, et al. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 2005; 44: 1135-64
26. Zhang J, Tian Q, Yung Chan S, et al. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab Rev 2005; 37: 611-703
27. Tofolli G, Corona G, Basso B, et al. Pharmacokinetic optimisation of treatment with oral etoposide. Clin Pharmacokinet 2004; 43: 441-66
28. Brindley CJ, Antoniw P, Newlands ES, et al. Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratoma. Cancer Chemother Pharmacol 1985; 15: 66-71
29. Speth PA, van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 1988; 15: 15-31
30. Mross K, Maessen P, van der Vijgh WJ, et al. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 1988; 6: 517-26
31. Danesi R, Fogli S, Gennari A, et al. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 2002; 41: 431-44
32. Kasel D, Baumhäkel M, Fuhr U. Biodegradation of procarbazine by human liver microsomes. Int J Clin Pharmacol Ther 2000; 38: 153-5
33. Begg EJ, Atkinson HC, Gianarakis N. The pharmacokinetics of corticosteroid agents. Med J Aust 1987; 146: 37-41
34. Karlsson MO, Sheiner LB. The importance of modelling inter-occasion variability in population pharmacokinetics. J Phar macokinet Biopharm 1993; 21: 735-50
35. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
36. Ishibashi T, Yano Y, Oguma T. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br J Clin Pharmacol 2003; 56: 205-13
37. Powis G, Reece P, Ahmann DL, et al. Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 1987; 20: 219-22
38. Nguyen L, Chatelut E, Chevreau C, et al. Population pharmacokinetics of total and unbound etoposide. Cancer Chemother Pharmacol 1998; 41: 125-32
39. Freyer G, Tranchand B, Ligneau B, et al. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. Br J Clin Pharmacol 2000; 50: 315-24
40. Li J, Gwilt PR. The effect of age on the early disposition of doxorubicin. Cancer Chemother Pharmacol 2003; 51: 395-402
41. Gurney H: How to calculated the dose of chemotherapy. Br J Cancer 2002; 86: 1297-302
42. Greco FA, Hainsworth JD: Prolonged administration of low-daily-dose etoposide: a superior dosing schedule? Cancer Chemother Pharmacol 1994; 34 Suppl: S101-4
43. Clark PI, Slevin ML, Joel SP, et al. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 1994; 12: 1427-35
44. Yule SM, Price L, McMahon AD, et al. Cyclophosphamide metabolism in children with non-Hodgkin's lymphoma. Clin Cancer Res 2004; 10: 455-60
45. Ayash LJ, Wright JE, Tretyakov O, et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992; 10: 995-1000
46. Petros WP, Hopkins PJ, Spruill S, et al. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol 2005; 23: 6117-25
47. Xie H, Griskevicius L, Stahle L, et al. Pharmacogenetics of cyclophosphamide in patients with haematological malignancies. Eur J Pharm Sci 2006; 27: 54-61
48. de Jonge ME, Huitema AD, Tukker AC, et al. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy. Clin Cancer Res 2005; 11: 273-83
49. McDonald GB, McCune JS, Batchelder A, et al. Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant. Clin Pharmacol Ther 2005; 78: 298-308
50. Fuchs M, Franklin J, Klimm B, et al. Mortality during treatment of patients with advanced Hodgkin's lymphoma undergoing dose escalated BEACOPP chemotherapy: an analysis of the German Hodgkin Study Group (GHSG) [abstract]. Blood 2005; 106: 2668
51. Zorsky PE, Perkins JB. Optimizing high-dose therapy using pharmacokinetic principles. Semin Oncol 1993; 20 (5 Suppl. 6): 2-18
52. Sandström M, Freijs A, Larsson R, et al. Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol 1996; 14: 1581-8
53. Chatelut E, Chevreau C, Blancy E, et al. Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma. Cancer Chemother Pharmacol 1990; 26: 365-8
54. Bielack SS, Erttmann R, Winkler K, et al. Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. Eur J Cancer Clin Oncol 1989; 25: 873-82
55. Hortobagyi GN. Anthracyclines in the treatment of cancer: an overview. Drugs 1997; 54 Suppl. 4: 1-7
56. Ploylearmsaeng S, Fuhr U, Jetter A. How may anticancer chemotherapy with 5-fluorouracil be individualized? Clin Pharmacokinet 2006; 45: 567-92
57. Özdemir V, Kalow W, Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10: 373-88
58. Van den Bongard HJ, Mathot RA, Beihnen JH, et al. Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet 2000; 39: 345-67